Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases

Hepatology

Volumn 54, Issue 4, 2011, Pages 1487-1489

  Coppola, Nicola ^a   Pisaturo, Mariantonietta ^a   Guastafierro, Salvatore ^b   Tonziello, Gilda ^a   Sica, Antonello ^b   Sagnelli, Caterina ^a   Ferrara, Maria Giovanna ^b   Sagnelli, Evangelista ^a,c  

^a Department of Public Medicine   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ENTECAVIR; FLUDARABINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TELBIVUDINE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIMIT OF DETECTION; LONGITUDINAL STUDY; MALE; OCCULT HEPATITIS C VIRUS INFECTION; ONCOHEMATOLOGICAL DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT;

EID: 80053327099     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24436     Document Type: Letter

References (8)

1. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? HEPATOLOGY 2009; 49: 665-675.
2. Carreño V, Bartolomé J, Castillo I, Quiroga JA. Hepatitis C Virus replication in patients with occult hepatitis C virus infection. HEPATOLOGY 2009; 49: 2128-2129.
3. Halfon P, Martinot-Peignoux M, Cacoub P. The myth of occult hepatitis C infection. HEPATOLOGY 2009; 50: 1675.
4. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, et al. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19: 2288-2292.
5. Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther 2008; 13: 307-318.
6. Halfon P, Bourlière M, Ouzan D, Sène D, Saadoun D, Khiri H, et al. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 2008; 46: 2106-2108.
7. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008; 83: 59-62.
8. Nicot F, Kamar N, Mariamé B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 2010; 23: 594-601.